Daily Medication Pearl: Natalizumab (Tysarbi)

Article

Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of: multiple sclerosis and Crohn disease.

Medication Pearl of the Day: Natalizumab (Tysarbi)

Indication: Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of multiple sclerosis (MS) and Crohn disease.

Insight:

  • Dosing: 300 mg infused intravenously over 1 hour, every 4 weeks. Do not give as an intravenous push or bolus.
  • Dosage forms: Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial for dilution prior to infusion.
  • Adverse events: Most common adverse reactions (incidence ³ 10%) with natalizumab in MS are headache, fatigue, arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea NOS, and rash.
  • Mechanism of action: Natalizumab binds to the a4-subunit of a4b1 and a4b7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the a4-mediated adhesion of leukocytes to their counter-receptor(s)

Source:

tysabri_prescribing_information.pdf (tysabrihcp.com)

Recent Videos
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Alzheimer and dementia clock drawing cognitive test -- Image credit: Jovana Milanko/Stocksy | stock.adobe.com
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Caregiver holding elderly man's hand -- Image credit: Chinnapong | stock.adobe.com
Health care worker looking at MRI scans of dementia -- Image credit: Atthapon | stock.adobe.com
Neurons in Alzheimer disease -- Image credit: Dr_Microbe | stock.adobe.com